The 10-day moving average for ACB crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
ACB moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +24.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 180 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 82 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
The 10-day RSI Indicator for ACB moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 13 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACB as a result. In 85 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.629) is normal, around the industry mean (6.379). P/E Ratio (-2.701) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The 10-day RSI Oscillator for SNDL moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In 23 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where SNDL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDL as a result. In 76 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for SNDL turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 35 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
SNDL broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
SNDL moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SNDL crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.
Following a +11.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDL advanced for three days, in 142 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 92 of 122 cases where SNDL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.327) is normal, around the industry mean (5.437). P/E Ratio (-17.688) is within average values for comparable stocks, (71.252). SNDL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.402). Dividend Yield (0.000) settles around the average of (0.088) among similar stocks. P/S Ratio (0.536) is also within normal values, averaging (5.308).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. SNDL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.
ACB | SNDL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 91 | |
PRICE GROWTH RATING 1..100 | 39 | 55 | |
P/E GROWTH RATING 1..100 | 98 | 61 | |
SEASONALITY SCORE 1..100 | 34 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNDL's Valuation (10) in the null industry is in the same range as ACB (24) in the Pharmaceuticals Other industry. This means that SNDL’s stock grew similarly to ACB’s over the last 12 months.
SNDL's Profit vs Risk Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that SNDL’s stock grew similarly to ACB’s over the last 12 months.
SNDL's SMR Rating (91) in the null industry is in the same range as ACB (96) in the Pharmaceuticals Other industry. This means that SNDL’s stock grew similarly to ACB’s over the last 12 months.
ACB's Price Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as SNDL (55) in the null industry. This means that ACB’s stock grew similarly to SNDL’s over the last 12 months.
SNDL's P/E Growth Rating (61) in the null industry is somewhat better than the same rating for ACB (98) in the Pharmaceuticals Other industry. This means that SNDL’s stock grew somewhat faster than ACB’s over the last 12 months.
| ACB | SNDL | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 68% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 73% |
| Advances ODDS (%) | 15 days ago 77% | 15 days ago 70% |
| Declines ODDS (%) | 1 day ago 84% | 3 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 83% |
| Aroon ODDS (%) | 2 days ago 71% | 1 day ago 75% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 1 FA rating(s) are green while SNDL’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 4 TA indicator(s) are bullish while SNDL’s TA Score has 4 bullish TA indicator(s).
ACB (@Pharmaceuticals: Generic) experienced а -11.55% price change this week, while SNDL (@Beverages: Alcoholic) price change was -3.60% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.75%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -8.43%.
The average weekly price growth across all stocks in the @Beverages: Alcoholic industry was -3.12%. For the same industry, the average monthly price growth was -11.27%, and the average quarterly price growth was -30.08%.
ACB is expected to report earnings on Feb 10, 2027.
SNDL is expected to report earnings on Mar 18, 2027.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Beverages: Alcoholic (-3.12% weekly)The alcoholic beverage market includes beer, wine, and spirits. From $230 billion in 2015, the industry has grown to around $250 billion by 2019. In recent years, alcoholic beverage makers have been looking to expand distribution and purchase channels, such as through online stores (e.g. e-commerce platform Drizly) and convenience stores. Anheuser-Busch In Bev and Diageo are major global alcoholic beverage companies, while U.S.-owned companies include Constellation Brands and Brown-Forman Corp. among several others.
A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.
| Ticker / NAME | Correlation To ACB | 1D Price Change % | ||
|---|---|---|---|---|
| ACB | 100% | -2.65% | ||
| CGC - ACB | 69% Closely correlated | -5.63% | ||
| SNDL - ACB | 65% Loosely correlated | N/A | ||
| TLRY - ACB | 62% Loosely correlated | -4.26% | ||
| TRLV - ACB | 58% Loosely correlated | -0.50% | ||
| OGI - ACB | 56% Loosely correlated | -4.29% | ||
More | ||||
A.I.dvisor indicates that over the last year, SNDL has been closely correlated with CGC. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if SNDL jumps, then CGC could also see price increases.
| Ticker / NAME | Correlation To SNDL | 1D Price Change % | ||
|---|---|---|---|---|
| SNDL | 100% | N/A | ||
| CGC - SNDL | 77% Closely correlated | -5.63% | ||
| TLRY - SNDL | 76% Closely correlated | -4.26% | ||
| CRON - SNDL | 73% Closely correlated | -0.63% | ||
| OGI - SNDL | 68% Closely correlated | -4.29% | ||
| ACB - SNDL | 65% Loosely correlated | -2.65% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LQDI | 24.85 | 0.02 | +0.08% |
| iShares Inflation Hedged Corporate Bond ETF (LQDI) | |||
| KPDD | 4.86 | N/A | N/A |
| KraneShares 2x Long PDD Daily ETF (KPDD) | |||
| EMXC | 84.51 | -0.47 | -0.55% |
| iShares MSCI Emerging Markets ex China ETF (EMXC) | |||
| BRIE | 28.64 | -0.21 | -0.73% |
| MFS Blended Research International Equity ETF (BRIE) | |||
| CANC | 38.86 | -0.66 | -1.67% |
| Tema Oncology ETF (CANC) | |||